New clinical concepts after the ONTARGET trial

References

• Yusuf S, Teo KK, Pogue J et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N. Engl. J. Med.358, 1547–1559 (2008).
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Assessment Report for Micardis. International non-proprietary name/common name: telmisartan. Procedure No. EMEA/H/C/000209/II/0073. European Medicines Agency, London, UK (2010).
   Google Scholar
• Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcome Prevention Evaluation study investigators. N. Engl. J. Med.342, 145–153 (2000).
   PubMed Web of Science ®Google Scholar
• Fox KM. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet362, 782–788 (2003).
   PubMed Web of Science ®Google Scholar
• Braunwald E, Domanski MJ, Fowler SE et al.; PEACE Trial Investigators. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N. Engl. J. Med.351, 2058–2068 (2004).
   PubMed Web of Science ®Google Scholar
• Mancia G, De Backer G, Dominiczak A et al. 2007 guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J. Hypertens.25, 1105–1187 (2007).
   PubMed Web of Science ®Google Scholar
• Sleight P, Redon J, Verdecchia P, Mancia G et al.; ONTARGET investigators. Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study. J. Hypertens.27, 1360–1369 (2009).
   PubMed Web of Science ®Google Scholar
• Cooper-DeHoff RM, Gong Y, Handberg EM et al. Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA304, 61–68 (2010).
   PubMed Web of Science ®Google Scholar
• Haller H, Ito S, Izzo JL Jr; ROADMAP Trial Investigators. Olmesartan for the delay or prevention of microalbuminuria in Type 2 diabetes. N. Engl. J. Med.364, 907–917 (2011).
   PubMed Web of Science ®Google Scholar
• Cushman WC, Evans GW, Byington RP et al.; ACCORD Study Group. Effects of intensive blood-pressure control in Type 2 diabetes mellitus. N. Engl. J. Med.362, 1575–1585 (2010).
   PubMed Web of Science ®Google Scholar
• Mancia G, Laurent S, Agabiti-Rosei E et al. Reappraisal of European guidelines on hypertension management: a European Society Hypertension Task Force document. J. Hypertens.27, 2121–2158 (2009).
   PubMed Web of Science ®Google Scholar
• Gunarathne A, Patel JV, Gammon B, Gill PS, Hughes EA, Lip GY. Ischemic stroke in South Asians: a review of the epidemiology, pathophysiology, and ethnicity-related clinical features. Stroke40, e415–e423 (2009).
   Web of Science ®Google Scholar
• Yusuf S, Teo K, Anderson C et al.; Telmisartan Randomised Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (TRANSCEND) Investigators. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet372, 1174–1183 (2008).
   PubMed Web of Science ®Google Scholar
• Yusuf S, Diener HC, Sacco RL et al.; PROFESS Study Group. Telmisartan to prevent recurrent stroke and cardiovascular events. N. Engl. J. Med.359, 1225–1237 (2008).
   PubMed Web of Science ®Google Scholar
• MacMahon S, Peto R, Cutler J et al. Blood pressure, stroke, and coronary heart disease. Part 1. Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet335, 765–774 (1990).
   PubMed Web of Science ®Google Scholar
• Zanchetti A, Ruilope LM. Antihypertensive treatment in patients with Type-2 diabetes mellitus: what guidance from recent controlled randomized trials? J. Hypertens.20, 2099–2110 (2002).
   PubMed Web of Science ®Google Scholar
• Banegas JR, Messerli FH, Waeber B et al. Discrepancies between office and ambulatory blood pressure: clinical implications. Am. J. Med.122, 1136–1141 (2009).
   PubMedGoogle Scholar
• Kjeldsen SE, Jamerson KA, Bakris GL et al. Avoiding Cardiovascular events through Combination therapy in Patients Living with Systolic Hypertension Investigators. Predictors of blood pressure response to intensified and fixed combination treatment of hypertension: the ACCOMPLISH study. Blood Press.17, 7–17 (2008).
   PubMed Web of Science ®Google Scholar
• Mann JFE, Schmieder RE, McQueen M et al.; ONTARGET investigators. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet372, 547–553 (2008).
   PubMed Web of Science ®Google Scholar
• Ruilope LM, Segura J, Fujita T, Ritz E. Renal and cardiovascular events: do they deserve the same consideration in clinical trials? J. Hypertens.27, 1743–1745 (2009).
   PubMedGoogle Scholar
• Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to Type 2 diabetes. N. Eng. J. Med.345, 851–860 (2001).
   PubMed Web of Science ®Google Scholar
• Cao JJ, Biggs ML, Barzilay J et al. Cardiovascular and mortality risk prediction and stratification using urinary albumin excretion in older adults ages 68-102: the Cardiovascular Health Study. Atherosclerosis197(2), 806–813 (2008).
   PubMedGoogle Scholar
• Appel LJ, Wright JT Jr, Greene T et al.; AASK Collaborative Research Group. Intensive blood-pressure control in hypertensive chronic kidney disease. N. Engl. J. Med.363, 918–929 (2010).
   PubMed Web of Science ®Google Scholar
• Pitt B, Zannad F, Remme WJ et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N. Engl. J. Med.341, 709–717 (1999).
   PubMed Web of Science ®Google Scholar
• Pitt B, Remme W, Zannad F et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N. Engl. J. Med.348, 1309–1321 (2003).
   PubMed Web of Science ®Google Scholar
• Zannad F, McMurray JJ, Krum H et al.; EMPHASIS-HF Study Group. Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms. N. Engl. J. Med.364(1), 11–21 (2010).
   PubMedGoogle Scholar
• Baigent C, Blackwell L, Emberson J et al.; Cholesterol Treatment Trialists’ Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet376, 1670–1681 (2010).
   PubMed Web of Science ®Google Scholar
• Cerezo C, Segura J, Banegas JR et al. Trends in albuminuria under renin–angiotensin system suppression. J. Hypertens. (Suppl. A), e446–e447 (2010).
   Google Scholar
• Gustafsson F, Segura J, Ruilope LM. How should we manage heart failure developing in patients already treated with ACE inhibitors and β-blockers for hypertension, diabetes or coronary disease. J. Hypertens.28, 1595–1598 (2010).
   PubMed Web of Science ®Google Scholar